Searched for
METROPOLIS HEALTHCARE EARNINGS
Open to 4-5 acquisitions, but at sensible valuations: Ameera Shah, promoter and executive chairperson, Metropolis HealthcareMetropolis Healthcare is set for its next growth phase. The diagnostic chain will focus on genomics and specialty diagnostics. Strategic ac...- Earnings are strong, but margin pain is coming; Dharmesh Kant on 3 sectors worth owning nowIndian corporate profits are currently strong. However, rising input costs present a significant challenge ahead. Investors should remain p...
- I-Sec upgrades Metropolis Healthcare to Buy, lowers target price to Rs 2,250ICICI Securities has upgraded Metropolis Healthcare to Buy, setting a target price of Rs 2,250. The company reported a net profit of Rs 31....
- Metropolis Q1 results: Net profit rises 31% to Rs 38 croreThe earnings for interest, tax, depreciation and ammortisation (EBITDA) before CSR and ESOP rose 20.2% YoY to Rs 80.5 crore in Q1. The EBIT...
- Metropolis Healthcare Q4 Results: Net profit rises 8% to Rs 36 croreThe diagnostic chain reported Rs 33.5 crore net profit in the corresponding quarter of the previous year. Revenue from operations grew by 1...
- Metropolis Healthcare Q3 Results: Net profit drops 25% to Rs 27 crore"The performance in Q3 was marginally impacted on account of heavy rainfall and floods in Chennai and adjacent areas in December 2023, lead...
- Fundamental Radar: Why Metropolis Health is a good contra play? Sandeep Raina explainsHowever, Sandeep Raina, executive vice president - research, Nuvama Professional Clients Group, believes that much of the concerns are abat...
- Hot Stocks: Brokerage views on Nykaa, Metropolis Healthcare, Gujarat Gas, Medanta and Zee EntertainmentFull business normalization is still a few quarters away. The global investment bank slashed FY23-25E EPS estimates by 7% to factor in a re...
- Pace of earnings downgrades picks up with cost inflation, demand slowdownAmong sectors, oil & gas, healthcare, PSU banks, and consumer durables have seen the biggest earnings downgrades. Earnings per share estima...
- Amazon, Walmart's Flipkart in talks to buy stake in $1.1 billion diagnostics chain Metropolis HealthcareThe company is in early discussions with several global strategic investors and other potential purchasers of the shares, said the people, ...
- Diagnostic industry has to first learn to tackle some challenges before trying to growThe diagnostic healthcare industry was among the few industries in the economy that had strong tailwinds during the pandemic.
- Diagnostic chains eye IPO route to raise fundsThe euphoria is aided by a massive spike in the share prices of already listed entities such as Metropolis Healthcare, Dr Lal Pathlabs, Med...
- Metropolis Healthcare jumps 9% as Q4 profit multipliesIn Q4, the company recorded its highest ever quarterly revenue largely led by a healthy recovery in non-Covid and increased Covid testing o...
- Nazara, Metro Health’s earnings announcements before board approval raise eyebrowsThe move has raises eyebrows among some market participants, who allege the companies may have violated rules.
- Metropolis Healthcare Q3 results: Net profit rises 40% to Rs 59 crConsolidated revenue from operations stood at Rs 274.77 crore for the quarter under consideration. It was Rs 222.85 crore for the same peri...
- Metropolis Healthcare Q4 results: Net profit declines 56% to Rs 15.49 croreThe company had posted a net profit of Rs 34.84 crore for the corresponding period of the previous fiscal.
- Makers of potential Covid drugs, testing cos may draw investorsCadila has 32 per cent market share in API hydroxychloroquine in the US.
- Diagnostic cos fall on Reliance Life’s proposed entryOn Monday, these three stocks fell between 1 per cent and 3 per cent.
- 3 stocks are in the pink of health in a choppy market, drawing eyeballsThyrocare has shed 7.27 per cent for the year to date.
- Metropolis: Tests OK, wait for listing to get clearer prognosisIn a highly fragmented, competitive, regional market, Metropolis is an organised national player.
Load More
